Patent ID: 7115607
Filing Date: 2006-10-03
Classification: A61K,A61P,C07D,C07K

Abstract:
1. A compound of Formula II wherein R 10 is selected from H, chloro or fluoro; wherein R 12 is wherein R 13a and R 13b are independently selected from H, phenyl, fluoro, iodo, bromo, chloro, phenyl, C 1-2 -alkyl, C 1-2 -haloalkyl, and C 1-2 -alkoxy; or wherein R 13a and R 13b together form an C 1-4 -alkenylenyl bridge; wherein R 14 is selected from R 19 R 20 N—, R 19 R 20 N—C 1-4 -alkyl, (R21R22N—) (O=)C-, C 1-4 -haloalkyl, C 2-4 -hydroxyalkyl, heterocyclyloxy-C 1-4 -alkyl, aryloxy-C 1-4 -alkyl and C 1-4 -alkoxycarbonyl; wherein R 15 is selected from H, C 1-2 -haloalkyl, C 1-4 -alkyl, halo, —OR 17 , and —N(R 17 ) 2 ; wherein R 16 is selected from 3-pyridyl, 4-pyridyl, 5-benzopyrrolyl, 2-benzofuran, 2-benzothienyl, 6-quinolyl, thienyl, 4-piperidyl, N-methyl-4-piperidyl, N-methyl-2-piperidyl, N-ethyl-4-piperidyl, N-isobutyl-4-piperidyl, 3-piperidyl and 3-azetidinyl optionally N-substituted with a substituent selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, cyclohexylmethyl and benzyl; wherein R 17 is selected from H, C 1-4 -alkyl, C 3-7 -cyclhoalkyl-(CH 2 ) n —, and aryl-(CH 2 ) n —; wherein R 19 is selected from H, R 23 SO 2 —, C 1-6 -alkyl, C 3-7 -cycloalkyl-(CH 2 ) n —, amino-C 1-6 -alkyl, C 1-6 -alkylamino-C 1-6 -alkyl, C 3-7 -cycloalkylamino-C 1-6 -alkyl, C 3-7 -cycloalkyl-C 1-6 -alkylamino-C 1-6 -alkyl, heteroarylamino-C 1-6 -alkyl, heteroaryl-C 1-6 -alkylamino-C 1-6 -alkyl, arylamino-C 1-6 -alkyl, aryl-C 1-6 -alkylamino-C 1-6 -alkyl, heteroaryloxy-C 1-6 -alkyl, heteroaryl-C 1-6 -alkyloxy-C 1-6 -alkyl, aryloxy-C 1-6 -alkyl, aryl-C 1-6 -alkyloxy-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkylthio-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkylcarbonyl, C 1-6 -alkoxycarbonyl, C 1-6 -alkoxy-C 1-6 -alkylcarbonyl, C 1-6 -alkylaminocarbonyl, arylcarbonyl, aralkylcarbonyl, C 3-7 -cycloalkylcarbonyl, C 3-7 -cycloalkyl-C 1-6 -alkylcarbonyl, heteroaryl-C 1-6 -alkylcarbonyl and heteroarylcarbonyl; wherein R 20 is selected from H, C 1-8 -alkyl, C 3-7 -cycloalkyl-(CH 2 ) n —, C 1-3 -alkylsulfonyl, amino-C 1-3 -alkylamino, heterocyclyl-(CH 2 ) n —, and aryl-(CH 2 ) n —; alternatively R 19 and R 20 together with the nitrogen atom form a 4-8 membered heterocyclic ring; wherein R 21 is selected from H, C 1-6 -alkyl, C 2-6 -alkenyl, C 1-6 -alkylthio-C 1-6 -alkyl, C 1-6 -alkylcarbonylamino-C 1-6 -alkyl, amino-C 1-6 -alkyl, heterocyclyl-(CH 2 ) n —, C 3-7 -cycloalkyl-(CH 2 ) n —, and aryl-(CH 2 ) n —; wherein R 22 is selected from H, C 1-6 -alkyl, C 3-7 -cycloalkyl-(CH 2 ) n —, heterocyclyl-(CH 2 ) n — and aryl-(CH 2 ) n —; alternatively R 21 and R 22 together with the amide nitrogen atom form a 4-7 membered saturated heterocyclic ring; wherein R 23 is selected from H, C 1-6 -alkyl, C 3-7 -cycloalkyl-(CH 2 ) n —, heterocyclyl-(CH 2 ) n — and aryl-(CH 2 ) n —; wherein n is 0, 1, 2 or 3; and wherein m is 0, 1 or 2; wherein aryl, heterocyclyl are optionally substituted with one or more substituents selected from C 1-2 -haloalkyl, C 1-3 -alkyl, C 3-6 -cycloalkyl-(CH 2 ) n —, chloro, fluoro, —OR 17 , —NR 17 CO 2 R 17 , —NR 17 SO 2 R 17 , N(R 17 ) 2 , cyano, —COR 17 , —C(R 17 ) 2 N(R 17 ) 2 , nitro, —SO 2 N(R 17 ) 2 , —S(O) m R 17 , and C 1-3 -haloalkoxy; and a pharmaceutically-acceptable salt thereof.